ϩ transport by ϳ70%. The inhibitory effect of BAY 39-9437 was concentration dependent, with a half-maximal inhibitory concentration of ϳ25 nM. Na ϩ transport was restored to control levels, with a half-life of ϳ15 min, on washout of BAY 39-9437. In addition, trypsin (1 M) rapidly reversed the inhibitory effect of BAY 39-9437. These data indicate that Na ϩ transport in HBE cells is activated by a BAY 39-9437-inhibitable, endogenously expressed serine protease. BAY 39-9437 inhibition of this serine protease maybe of therapeutic potential for the treatment of Na ϩ hyperabsorption in CF.
cystic fibrosis; Kunitz-type serine protease inhibitor; channel-activating protease; short-circuit current; primary cultures; epithelial sodium channel CYSTIC FIBROSIS (CF) is characterized by abnormalities in anion secretion and Na ϩ absorption in the airways (2, 3, 15, 22) . Although a great deal is known about the regulation of anion secretion, the underlying mechanisms regulating airway Na ϩ absorption are poorly understood. Recent studies (6, 27, 28) have demonstrated a novel extracellular serine protease-mediated signaling pathway for the modulation of amiloridesensitive epithelial Na ϩ channels (ENaCs). Amphibian and murine homologs of a cation channel-activating protease (CAP1) have been identified and are expressed in several epithelial tissues including kidney, prostate, salivary glands, colon and lung. Xenopus CAP1 (xCAP1) and murine CAP1 (mCAP1) share a 50% homology, whereas mCAP1 is 80% homologous with human prostasin (28) . Prostasin is also expressed in epithelial tissues, including the lung (30, 31) . Coexpression of xCAP1 (6, 27) or mCAP1 (28) with Xenopus, rat, or human ENaCs in Xenopus oocytes caused a severalfold increase in the amiloride-sensitive Na ϩ current. Aprotinin, a bovine-derived serine protease inhibitor, blocked the activation of ENaCs by CAP1. Aprotinin also inhibited the baseline Na ϩ transport in cultures of A6 cells, an amphibian renal cell line (27) and mpkCCD C14 cells, a murine renal cell line (28) .
The studies reported here were undertaken to test the hypothesis that Na ϩ transport in human bronchial epithelial (HBE) cells is regulated by a protease-mediated mechanism. To test this hypothesis, we first investigated the effects of several protease inhibitors for their potential effects on the amiloride-sensitive shortcircuit current (I sc ) in HBE cells. The results from these initial studies demonstrated that aprotinin inhibited HBE cell Na ϩ transport. In contrast, two other serine protease inhibitors, soybean trypsin inhibitor (SBTI) and ␣ 1 -antitrypsin (␣ 1 -AT), did not inhibit HBE cell Na ϩ transport. The unique feature of aprotinin that defines the protease-inhibitory site of this bovine protein is the Kunitz domain (11, 12) . A search for a human Kunitz-type serine protease inhibitor was made and led to the development of the recombinant protein BAY 39-9437. The studies reported here demonstrate the inhibitory effects of BAY 39-9347 on non-CF and CF HBE cell Na ϩ absorption.
METHODS
Primary cultures of HBE cells. HBE cells were obtained from excess pathological tissue remaining after lung transplantation under a protocol approved by the University of Pittsburgh (Pittsburgh, PA) Investigational Review Board. Tissue expressing wild-type CF transmembrane conductance regulator (CFTR) was obtained after lung transplantation for a variety of pathological conditions including bronchiectasis, emphysema, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis, and scleroderma. The CFTR genotype of the CF tissues was determined by allele-specific hybridization (performed at Genzyme, Framingham, MA). All cells were isolated from second through sixth generation bronchi in both wild-type CFTR-expressing (non-CF) and CF HBE cells. The bronchi were incubated overnight at 4°C in MEM containing 0.1% protease XIV, 0.01% deoxyribonuclease, and 1% fetal bovine serum (FBS). The epithelial cells were removed from the underlying musculature by blunt dissection, isolated by centrifugation, and washed in MEM containing 5% FBS. After centrifugation, the cells were resuspended in bronchial epithelial growth medium (Clonetics, San Diego, CA). The cells were then plated into human placental collagen-treated T-25 tissue culture flasks. On reaching 80-90% confluence, the cells were trypsinized (0.1%), resuspended in MEM plus 5% FBS, and seeded onto human placental collagen-coated Costar Transwell filters (0.33 cm 2 ) at a density of ϳ2 ϫ 10 6 /cm 2 . After 24 h, the medium was changed to DMEM-F-12 medium (1:1) plus 2% Ultroser G (BioSepra), and an air interface at the apical membrane was established. The medium bathing the basolateral surface was changed every 48 h. Measurements of I sc were performed after ϳ10-20 additional days in culture.
I sc measurements. Costar Transwell cell culture inserts were mounted in Costar Ussing chambers, and the cultures were continuously short-circuited with an automatic voltage clamp (Department of Bioengineering, University of Iowa, Iowa City, IA). Transepithelial resistance was measured by periodically applying a 2-mV bipolar pulse and calculated with Ohm's law. The bath solution contained (in mM) 120 NaCl, 25 NaHCO 3, 3.3 KH2PO4, 0.8 K2HPO4, 1.2 MgCl2, 1.2 CaCl2, and 10 glucose. The pH of this solution was 7.4 when gassed with a mixture of 95% O2-5% CO2 at 37°C. The amiloride-sensitive Isc was taken as a measure of net electrogenic Na ϩ transport. Materials. Aprotinin, SBTI, ␣1-AT, trypsin, and amiloride were from Sigma and were dissolved in phosphate-buffered saline (PBS) at 1,000-fold the required experimental concentrations. BAY 39-9437 is a 170-amino acid human serine protease inhibitor (7, 17) that was recombinantly expressed in Chinese hamster ovary (CHO) cells. The secreted protein was chromatographically purified from the culture medium.
Data analysis. All data are presented as means Ϯ SE; n is the number of experiments. Apparent inhibitory constant (K i) values were obtained with nonlinear curve-fitting routines in SigmaPlot (Jandel Scientific, San Rafael, CA). Statistical analysis was performed with Student's t-test. A value of P Ͻ 0.05 was considered significant.
RESULTS
The studies reported here were performed on HBE cultures with cells derived from five patients expressing wild-type CFTR (non-CF cells) and seven CF patients (CF cells). Two of the non-CF patients were diagnosed with emphysema or COPD, one with idiopathic pulmonary fibrosis, one with fibrotic connective tissue disease, and one with scleroderma. The CFTR genotype of the seven CF patients is given in Effects of protease inhibitors on Na ϩ transport across HBE cultures. In the first series of experiments, we investigated the effects of several protease inhibitors for their potential effects on Na ϩ transport across HBE cultures. A baseline I sc was first measured after a 20-min equilibration period, at which time the protease inhibitor was added to the mucosal bath. After 90 min, the I sc was again recorded, and amiloride (10 M) was then added to the mucosal bath. After an additional 5 min, the I sc was again recorded. Figure 1 summarizes the results of the effects of several protease inhibitors on the I sc across CF cells with the above protocol. Control cultures were given an equivalent volume of PBS and studied in parallel with the protease-treated cultures. The I sc of the PBS-treated cultures was stable over a 90-min period. Amiloride caused an inhibition of 34 Ϯ 3.8 A/cm 2 (n ϭ 29) in the PBS-treated cultures. 
CFTR, cystic fibrosis transmembrane conductance regulator. In contrast, aprotinin reduced the I sc from a baseline value of 37 Ϯ 2.9 A/cm 2 to a value of 15 Ϯ 3.5 A/cm 2 (n ϭ 9) after 90 min and amiloride caused a further inhibition of 9.3 Ϯ 3.9 A/cm 2 . Thus aprotinin caused a significant inhibition in the amiloride-sensitive I sc compared with the PBS-treated control cultures (P Ͻ 0.001). SBTI and ␣ 1 -AT did not inhibit the I sc or alter the amiloride-sensitive current ( Fig. 1) . Similar results were obtained with cells from non-CF patients.
These results demonstrate that Na ϩ transport in HBE cells is regulated by an aprotinin-sensitive mechanism as previously shown in studies on renal epithelial cells and ENaC expression studies in Xenopus oocytes (6, 27, 28) . Aprotinin is a serine protease inhibitor of bovine origin and a potent inhibitor of trypsin (11, 12) . Although SBTI and ␣ 1 -AT are also serine protease inhibitors, only aprotinin contains a Kunitz domain, the protease-inhibitory active site. Reasoning that the Kunitz domain was the essential feature of the inhibitory effect of aprotinin on Na ϩ transport, we searched for a human Kunitz-type protease inhibitor. BAY 39-9437 is such a protein and is further described in DISCUSSION. In BAY 39-9437 inhibition of HBE Na ϩ transport, we document the inhibitory effects of BAY 39-9437 on Na ϩ transport across non-CF and CF HBE cell cultures.
BAY 39-9437 inhibition of HBE Na ϩ transport. The inhibitory effects of BAY 39-9437 were completely reversed by the addition of trypsin to the mucosal solution (Fig. 6B) . In the experiment shown in (Fig. 6A) . Similar results were obtained with PBS-and BAY 39-9437-treated non-CF cells (data not shown).
In a second series of experiments designed to investigate the reversible inhibition of Na ϩ transport by BAY 39-9437, CF cells were incubated overnight with 25 l of PBS or PBS plus 470 nM BAY 39-9437 on the apical surface. The cells were then washed and placed in Ussing chambers, and the I sc was monitored. Overnight treatment with BAY 39-9437 caused a similar degree of inhibition in Na ϩ transport as observed after a 90-min treatment compared with that in PBS-treated cells (PBS treated: 50.8 Ϯ 2.6 A/cm 2 , n ϭ 25; BAY 39-9437 treated: 15.5 Ϯ 2.8 A/cm 2 , n ϭ 14). However, in contrast to the PBS-treated cells, the BAY 39-9437-treated cells showed a steady rise in I sc over a 45-min period to a new higher plateau value that was nearly equal to the initial I sc of the PBS-treated cells (Fig. 7) . The addition of trypsin (1 M) to the mucosal bath caused little change in the I sc of PBS-treated cells (Ͻ2.5 Ϯ 1.3 A/cm 2 ; n ϭ 9) as previously shown in Fig.  6 . In contrast, trypsin caused a rapid rise in the I sc of BAY 39-9437-treated cells, and the magnitude of this increase was greater in cells left for 15 min compared with cells left for 45 min (Fig. 7, B and C, respectively) . The results shown in Fig. 7 are representative of six similar experiments. Trypsin added at 15 min increased the I sc by 27 Ϯ 60 A/cm 2 and at 45 min by only 12 Ϯ 4.2 A/cm 2 in the BAY 39-9437-treated cells. These results demonstrate that the effects of BAY 39-9437 are reversible after a wash, with a t1⁄2 of ϳ15 min, and suggest that the activity of an endogenous protease is preserved after BAY 39-9437 treatment and washout.
DISCUSSION
BAY 39-9437 is a recombinant human serine protease inhibitor. The natural protein is a 252-amino acid protein composed of a signal peptide, two proteasebinding Kunitz domains, a transmembrane domain, and an intracellular domain. This protein was originally identified and isolated from the placenta and is referred to as placental bikunin (7, 17) . Northern blot analysis demonstrated the expression of placental bikunin in pancreas, kidney, brain, heart, and lung. The gene for placental bikunin was mapped to chromosome 19q13 (17) , and it is noteworthy that a CF modifier gene has been mapped to this same locus (33) . Loss of function mutations in placental bikunin are expected to increase the severity of CFTR disease, causing mutations, whereas an increase in the expression or activity of placental bikunin should diminish the severity of CFTR disease, causing mutations. The recombinant product BAY 39-9437 is a protein of 170 amino acid residues. BAY 39-9437 was expressed in CHO cells as a secreted form of placental bikunin lacking the transmembrane and intracellular domains such that it is composed of the signal peptide and the two extracellular Kunitz domains. Both placental bikunin and BAY 39-9437 inhibit trypsin (K i ϭ 0.01 nM), plasmin (K i ϭ 0.1 nM), and kallikrein (K i ϭ 0.3 M) at a 2:1 enzyme-to-inhibitor binding stoichiometry (7, 17) . However, placental bikunin and BAY 39-9437 do not inhibit urokinase, tissue plasminogen activator, or elastase at concentrations up to 1 M (7, 17).
The studies reported here demonstrate that BAY 39-9437 is a potent inhibitor of electrogenic Na ϩ transport in HBE cells. The Na ϩ transport inhibitory effects of BAY 39-9437 develop slowly, with a t1⁄2 of ϳ45 min (Figs. 2, 3 , and 6), and are reversible on washing, with a t1⁄2 of ϳ15 min (Fig. 7) , or develop rapidly with the addition of trypsin (Figs. 6 and 7) . The inhibitory effects of BAY 39-9437 on Na ϩ transport were concentration dependent and well described by a simple Michaelis-Menten inhibition function, with a K1⁄2 of ϳ25 nM in both non-CF and CF cells. These results do not preclude the possibility that both Kunitz domains participate in the inhibition of Na ϩ transport. However, they do suggest that there is no cooperativity between the two domains if indeed both Kunitz domains participate. BAY 39-9437 (470 nM) caused approximately the same degree of inhibition in the amiloride-sensitive I sc in non-CF (68%) and CF (72%) cells. The inhibitory effect of BAY 39-9437 was nearly completely reversed after a wash with an inhibitor-free solution. I sc increased, with a t1⁄2 of ϳ15 min, after removal of BAY 39-9437, suggesting that the activity of the ENaC-activating protease was preserved after BAY 39-9437 treatment. The inhibition of Na ϩ transport by BAY 39-9437 could also be rapidly reversed by the addition of trypsin to the mucosal bath. Mucosal trypsin had no effect on the baseline I sc or the 90-min I sc in PBS-treated non-CF or CF HBE cells. Only after inhibition with BAY 39-9437 was the stimulation of an amiloride-sensitive I sc with trypsin observed.
Our working hypothesis for the protease-mediated modulation and inhibition of HBE Na ϩ transport by BAY 39-9437 is illustrated in Fig. 8 . As originally suggested for the modulation of ENaC in renal epithelia (6, 27, 28), we propose that there is a CAP1-like protease in the apical membrane of HBE cells. ENaC is inserted into the apical membrane as an inactive or partially active channel where it is activated by an apical membrane CAP1-like protease. Active ENaC remains in the apical membrane for a t1⁄2 of ϳ45 min when it is then retrieved, probably ubiquitinated, and degraded (25) . The addition of a CAP1 inhibitor such as BAY 39-9437 prevents the activation of ENaC by CAP1. The addition of an exogenous protease such as trypsin can circumvent the inhibition of CAP1 and cause the activation of ENaC.
The molecular identity of the HBE cell CAP1-like protease remains to be established, but one possible candidate is prostasin (30) (31) (32) . In support of this notion, prostasin shares an 80% homology with mCAP1 and 50% homology with xCAP1. Moreover, prostasin was shown to be inhibited by aprotinin but not by SBTI (30) , results consistent with the inhibition of Na ϩ transport by aprotinin but not by SBTI (Fig. 1) . The prostatin gene (PRSS8) has been localized to chromosome 16p11.2 (21) and is another potential gene that could act as a CF modifier gene. Prostasin is synthesized by the cell as a preproenzyme and may remain on the plasma membrane or be released from the cell surface as a secreted protein (30, 31) . The results shown in Fig. 7 suggest that the protease responsible for the activation of ENaC in HBE cells is not readily washed off and thus may remain as a membraneanchored protein. The enzymes involved in the synthesis of prostasin and other CAP1-like proteases are unknown. The substrate for the CAP1-like proteases is also unknown. Initial experiments suggest that ENaC may not be the CAP1 substrate (6, 27) . However, it remains possible that ENaC is a protease-activated channel. If ENaC is not the CAP1 substrate, it will be important to identify the substrate as well as the signal transduction cascade that leads to the activation of ENaC. Given the emergence of protease-activated receptors (PARs) that are G protein coupled to intracellular signal transduction cascades (8) , one may speculate that CAP1 acts on a novel PAR to cause the activation of ENaC. Clearly, additional studies are necessary to determine whether ENaC is a proteaseactivated channel or to identify the CAP1-activated PAR involved in the regulation of ENaC. Xenopus oocyte expression studies (6, 27) suggest that CAP1 activation of ENaC involves an increase in the channel open probability and not an increase in the number of channels, results that are consistent with the model shown in Fig. 8 . Prolonged overnight incubation with aprotinin or BAY 39-9437 did not completely inhibit the amiloride-sensitive I sc in HBE cells (Fig. 7) . These results suggest that ENaC may be inserted into the Although controversy abounds in the CF research community regarding the composition and volume of the airway surface liquid in normal and CF airways (29) , there is unanimous agreement that improving the clearance of mucus in CF patients would be of major therapeutic benefit. Indeed, impaired mucociliary clearance is a clinical feature of many airway diseases including CF (20, 23) . The result of impaired mucociliary clearance is mucus retention and accumulation that appear to contribute to the severity of the disease. The inhibition of Na ϩ transport is anticipated to improve mucociliary clearance. Support for this logic is seen in another genetic disease, pseudohypoaldosteronism, caused by loss of function mutations in ENaC (5, 15, 26) . These patients display a fourfold increase in mucociliary transport compared with control patients (14) . Several attempts have been made with amiloride to show the therapeutic benefit of inhibiting Na ϩ transport in CF patients (4, 13, 16) . However, the results of these trials have been disappointing. The weak affinity of amiloride for ENaC (K i ϭ 300 nM) and the rapid clearance of this low molecular mass compound from the airways (1, 18, 19) are thought to be important reasons for the poor efficacy of amiloride. The in vitro studies reported here indicate that BAY 39-9437 has a 10-fold improved potency for the inhibition of ENaC compared with amiloride (25 vs. 300 nM). Moreover, as a 21-kDa recombinant protein, BAY 39-9437 is expected to have a longer residence time in the airways compared with that of amiloride. Thus if BAY 39-9437 can be delivered to the airways, it should inhibit Na ϩ transport and thereby improve mucociliary clearance. Animal studies reported by Newton et al. (21) document a decrease in the tracheal transepithelial potential difference caused by the local instillation of BAY 39-9437, results consistent with the inhibition of Na ϩ transport. Most importantly, BAY 39-9437 caused a twofold increase in tracheal mucociliary clearance. Thus we are optimistic that the human recombinant serine protease inhibitor BAY 39-4937 may be of therapeutic benefit in the treatment of CF.
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